@article{243b4014acdb4482b226024bca7778f7,
title = "Efficacy and safety of bevacizumab plus erlotinib in patients with renal medullary carcinoma",
abstract = "Purpose: To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC. Methods: We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution. Results: Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). Tumor burden was reduced in seven patients (70%) in total, and in three out of five patients (60%) that had received three or more prior therapies. The median progression-free survival (PFS) was 3.5 months (95% CI, 1.8–5.2). The median overall survival (OS) from bevacizumab plus erlotinib initiation was 7.3 months (95% CI, 0.73–13.8) and the median OS from diagnosis was 20.8 months (95% CI, 14.7–26.8). Bevacizumab plus erlotinib was well tolerated with no grade ≥4 adverse events and one grade 3 skin rash. Dose reduction was required in one patient (10%). Conclusions: Bevacizumab plus erlotinib is clinically active and well tolerated in heavily pre-treated patients with RMC and should be considered a viable salvage strategy for this lethal disease.",
keywords = "Aerobic glycolysis, Bevacizumab, Erlotinib, Platinum-based chemotherapy, Renal medullary carcinoma",
author = "Wiele, {Andrew J.} and Surasi, {Devaki Shilpa} and Priya Rao and Kanishka Sircar and Xiaoping Su and Bathala, {Tharakeswara K.} and Shah, {Amishi Y.} and Eric Jonasch and Cataldo, {Vince D.} and Giannicola Genovese and Karam, {Jose A.} and Wood, {Christopher G.} and Tannir, {Nizar M.} and Pavlos Msaouel",
note = "Funding Information: This work was supported in part by the Cancer Center Support Grant to The University of Texas MD Anderson Cancer Center (grant number P30 CA016672) from the National Cancer Institute of the National Institutes of Health. PM is supported by a Young Investigator Award from the Kidney Cancer Association, a Career Development Award from the American Society of Clinical Oncology, a Concept Award from the United States Department of Defense, and by the MD Anderson Khalifa Scholar Award.Conflicts of Interest: A.Y.S. has received honoraria for service on scientific advisory boards for Pfizer, Exelixis, BMS, Roche, and Eisai; and research funding from BMS, Eisai, and EMD Serono. E.J. has received honoraria for service on scientific advisory boards for Eisai, Exelixis, Novartis, Merck, Pfizer, and Roche; and research funding from Exelixis, Merck, Pfizer. Funding Information: Funding: This work was supported in part by the Cancer Center Support Grant to The University of Texas MD Anderson Cancer Center (grant number P30 CA016672) from the National Cancer Institute of the National Institutes of Health. PM is supported by a Young Investigator Award from the Kidney Cancer Association, a Career Development Award from the American Society of Clinical Oncology, a Concept Award from the United States Department of Defense, and by the MD Anderson Khalifa Scholar Award. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = may,
day = "1",
doi = "10.3390/cancers13092170",
language = "English (US)",
volume = "13",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",
}